Brain and behavior changes with tirzepatide stop and restart
Part of Mental health clinical trials.
This study looks at how your brain and behavior change when you stop and then restart the weight loss drug tirzepatide. It will help researchers understand what happens during treatment breaks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You are currently taking the weight loss drug tirzepatide (Mounjaro or Zepbound).
- You are a patient at the UT Southwestern Weight Wellness Clinic.
- You can understand English and give consent.
- You do not have type 2 diabetes, an eating disorder, or a serious neurological condition.
- You have no metal implants or devices that would prevent an MRI (like a pacemaker, metal screws, or clips).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
This trial tests whether a weekly injection called tirzepatide (a diabetes and weight-loss medication) can help people with obesity and stimulant use disorder reduce stimulant use and lose weight. It aims to see if treating both conditions together improves outcomes.
This trial examines how well tirzepatide works for weight loss in people with obesity, and how it's actually used in daily life. It may be an option if you haven't tried other obesity treatments and don't have diabetes.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests a medication called tirzepatide (a type of GLP-1 drug) to see how it affects muscle and bone health during weight loss. It is for people with obesity who are not menopausal and do not have diabetes or bone disease.
Hear when a new Substance Use Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.